- Home
- NGS vs TNGX Comparison
NGS vs TNGX Comparison
Compare NGS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- TNGX
- Stock Information
- Founded
- NGS 1998
- TNGX 2014
- Country
- NGS United States
- TNGX United States
- Employees
- NGS N/A
- TNGX N/A
- Industry
- NGS Oilfield Services/Equipment
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- TNGX Health Care
- Exchange
- NGS Nasdaq
- TNGX Nasdaq
- Market Cap
- NGS N/A
- TNGX 317.4M
- IPO Year
- NGS 2002
- TNGX N/A
- Fundamental
- Price
- NGS $20.11
- TNGX $1.10
- Analyst Decision
- NGS Strong Buy
- TNGX Strong Buy
- Analyst Count
- NGS 1
- TNGX 7
- Target Price
- NGS $32.00
- TNGX $12.33
- AVG Volume (30 Days)
- NGS 71.1K
- TNGX 542.7K
- Earning Date
- NGS 05-12-2025
- TNGX 05-12-2025
- Dividend Yield
- NGS N/A
- TNGX N/A
- EPS Growth
- NGS 260.53
- TNGX N/A
- EPS
- NGS 1.37
- TNGX N/A
- Revenue
- NGS $156,742,000.00
- TNGX $42,069,000.00
- Revenue This Year
- NGS $12.87
- TNGX N/A
- Revenue Next Year
- NGS $15.40
- TNGX N/A
- P/E Ratio
- NGS $14.68
- TNGX N/A
- Revenue Growth
- NGS 29.36
- TNGX 15.17
- 52 Week Low
- NGS $16.70
- TNGX $1.11
- 52 Week High
- NGS $29.74
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- NGS 53.74
- TNGX 33.44
- Support Level
- NGS $17.63
- TNGX $1.38
- Resistance Level
- NGS $19.68
- TNGX $1.56
- Average True Range (ATR)
- NGS 1.00
- TNGX 0.16
- MACD
- NGS 0.28
- TNGX -0.01
- Stochastic Oscillator
- NGS 90.51
- TNGX 9.90
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.